# Catalent, Inc. – Consensus ‘hold’ rating and 13.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/catalent-inc.consensus-hold-rating-and-13.2-upside-potential/4121130277
- Published: 2023-10-20T14:31:13+01:00
- Author: Charlotte Edwards

**Catalent, Inc.** which can be found using ticker (CTLT) have now 14 analysts in
total covering the stock. The consensus rating is pointing to ‘hold’. The range 
between the high target price and low target price is between 58 and 44 calculating
the average target price we see $50.93. Given that the stocks previous close was
at $45.01 this would indicate that there is a potential upside of 13.2%. Also worth
taking note is the 50 day moving average now sits at $46.32 and the 200 day moving
average is $50.40. The market cap for the company is 7.78B. The stock price for 
the company is currently 43.14 USD

 The potential market cap would be $8,799,805,441 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 23.62 and
a 0.43% return on assets.

Catalent, Inc. is a provider of development and manufacturing solutions for drug,
cell and gene therapies biologics, vaccines, and consumer health products. The Company’s
segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery,
and Clinical Supply Services. Its Biologics segment provides development and manufacturing
for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene
therapies. Its Softgel and Oral Technologies segment provide formulation, development,
and manufacturing services for soft capsules, as well as large-scale manufacturing
of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation
development and manufacturing across a range of technologies along with integrated
downstream clinical development and commercial supply solutions. Its Clinical Supply
Services segment provides manufacturing, packaging, storage, distribution, and inventory
management for, drugs, biologics and clinical trials.

Share on: